Related Experiment Videos
[Ursodeoxycholic acid therapy in biliary cirrhosis]
L Herszényi1, L Szalay, Z Schaff
1Semmelweis Orvostudományi Egyetem, II. Belgyógyászati Klinika, Budapest.
Orvosi Hetilap
|September 19, 1993
Summary
Ursodeoxycholic acid (UDCA) therapy improved clinical outcomes in primary biliary cirrhosis patients. UDCA treatment demonstrated potential immunosuppressive effects, reducing IgG levels and natural killer cell activity.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Context:
- Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease.
- Ursodeoxycholic acid (UDCA) is a commonly used therapeutic agent for PBC.
- The immunomodulatory effects of UDCA in PBC require further elucidation.
Purpose:
- To evaluate the clinical efficacy and immunological effects of UDCA in female patients with primary biliary cirrhosis.
- To assess changes in liver function tests and immune parameters during UDCA therapy.
Summary:
- Six female PBC patients received UDCA (10 mg/kg/day) for up to nine months.
- Significant improvements were observed in liver function tests, including decreased gamma-GT, ALT, AST, bilirubin, alkaline phosphatase, cholesterol, and triglyceride levels.
- UDCA therapy led to a statistically significant reduction in IgG levels, natural killer (NK) cell activity, and spontaneous blast transformation, suggesting immunosuppressive properties.
Impact:
- UDCA therapy demonstrates clinical benefits in PBC patients.
- The findings suggest UDCA possesses immunomodulatory effects that may contribute to its therapeutic efficacy in PBC.
- This study supports the use of UDCA as an effective treatment for primary biliary cirrhosis.